Colombia sets Kaletra price ceiling
This article was originally published in Scrip
The Colombian government has set a maximum price for Abbott's Kaletra (lopinavir plus ritonavir), reducing the private sector price by around 55%. However, civil society is still pushing for the government to issue a compulsory licence.
You may also be interested in...
Meindert Boysen, head of NICE’s Centre For Health Technology Evaluation, shares advice for companies aiming to get their medicine to patients. His golden rules: engage in early advice and be more realistic about pricing.
In an exclusive interview with the Pink Sheet, senior NICE director Meindert Boysen reveals the best advice he ever received and how companies whose products are under review can improve their chances of success.
UK HTA body NICE is looking to the future and rethinking its approach to data and how they inform its guidance.